RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Molecular Partners Stock

Molecular Partners ROA 2024

Molecular Partners ROA

-0.31

Ticker

MOLN.SW

ISIN

CH0256379097

WKN

A12DEH

In 2024, Molecular Partners's return on assets (ROA) was -0.31, a -169.54% increase from the 0.45 ROA in the previous year.

Molecular Partners Aktienanalyse

What does Molecular Partners do?

Molecular Partners AG is a biopharmaceutical company based in Zurich, specializing in the research and development of novel therapies in the fields of cancer and ophthalmology. The company was founded in 2004 as a spin-off from the Swiss Federal Institute of Technology Zurich (ETHZ) and has since made significant progress in drug research and development. The business model of Molecular Partners is based on the development of so-called DARPins (Designed Ankyrin Repeat Proteins). DARPins are artificially created protein molecules that can be used as highly specific binding partners in drug research and development. Due to their modular structure and flexibility, DARPins can bind to a variety of target molecules, thus serving as a basis for the development of new therapies. The various divisions of Molecular Partners focus on the development of therapies in the areas of cancer and ophthalmology. In the field of cancer, the company has a number of promising drug candidates based on DARPins in preclinical and clinical development. One of the most promising candidates is MP0250, a bispecific DARPin that targets two targets and is intended to suppress cancer cell activity. In the field of ophthalmology, Molecular Partners is developing therapies for the treatment of retinal diseases and other eye diseases. One of the most promising candidates in this area is Abicipar, an anti-VEGF DARPin that can be used to treat wet age-related macular degeneration and other retinal diseases. Abicipar has already shown promising results in clinical trials and is currently being submitted for approval to US and European regulatory authorities. Molecular Partners has formed partnerships with leading pharmaceutical and biotech companies such as Amgen, Allergan, Novartis, and Nestlé Health Science to support the development and commercialization of their drug candidates. In addition, the company has entered into a number of licensing and collaboration agreements with other companies to advance the development of new therapies. Overall, Molecular Partners has made significant progress in the development of novel therapies in the fields of cancer and ophthalmology in recent years. The company has developed a unique platform technology on which a variety of therapies can be based, tailored to the specific needs of patients. With its strong partnerships and pipeline of drug candidates, Molecular Partners is well positioned to continue growing and developing new treatment options for patients in the coming years. Molecular Partners ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Molecular Partners's Return on Assets (ROA)

Molecular Partners's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Molecular Partners's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Molecular Partners's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Molecular Partners’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Molecular Partners stock

What is the Return on Assets (ROA) of Molecular Partners this year?

The Return on Assets (ROA) of Molecular Partners is -0.31 undefined this year.

What was the ROA of Molecular Partners compared to the previous year?

The ROA of Molecular Partners has increased by -169.54% compared to the previous year.

What consequences do high ROA have for investors of Molecular Partners?

A high ROA is advantageous for investors of Molecular Partners, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Molecular Partners?

A low ROA can be unfavorable for investors of Molecular Partners as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Molecular Partners affect the company?

An increase in ROA of Molecular Partners can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Molecular Partners impact the company?

A reduction in the ROA of Molecular Partners can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Molecular Partners?

Some factors that can influence the ROA of Molecular Partners include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Molecular Partners important for investors?

The ROA of Molecular Partners is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Molecular Partners take to improve ROA?

To improve ROA, Molecular Partners can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Molecular Partners pay?

Over the past 12 months, Molecular Partners paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Molecular Partners is expected to pay a dividend of 0 CHF.

What is the dividend yield of Molecular Partners?

The current dividend yield of Molecular Partners is .

When does Molecular Partners pay dividends?

Molecular Partners pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Molecular Partners?

Molecular Partners paid dividends every year for the past 0 years.

What is the dividend of Molecular Partners?

For the upcoming 12 months, dividends amounting to 0 CHF are expected. This corresponds to a dividend yield of 0 %.

In which sector is Molecular Partners located?

Molecular Partners is assigned to the 'Health' sector.

Wann musste ich die Aktien von Molecular Partners kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Molecular Partners from 9/29/2024 amounting to 0 CHF, you needed to have the stock in your portfolio before the ex-date on 9/29/2024.

When did Molecular Partners pay the last dividend?

The last dividend was paid out on 9/29/2024.

What was the dividend of Molecular Partners in the year 2023?

In the year 2023, Molecular Partners distributed 0 CHF as dividends.

In which currency does Molecular Partners pay out the dividend?

The dividends of Molecular Partners are distributed in CHF.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Molecular Partners

Our stock analysis for Molecular Partners Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Molecular Partners Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.